

AMENDMENTS TO THE CLAIMS

The following represents a complete listing of the claims in this application indicating the present status of each, including any amendments sought to be entered at this time. Any claims that have been canceled or withdrawn have been canceled or withdrawn without prejudice or disclaimer of any subject matter therein. The applicants specifically reserve the right to pursue any and all such claims in continuing and/or divisional applications. In this paper, claims 46 and 48-51 have been amended, claims 19-23, 34, 36-39 and 42-45 have been canceled and new claims 52-68 have been added.

Listing of the claims:

1-45 (canceled).

46 (currently amended). A disposal system for a skin-worn transdermal patch device containing residual amounts of an opioid substance after use thereof on a patient, said system comprising:

- (a) a disposable container separate from and independent of said skin-worn patch device and having an opening therein for receiving a skin-worn patch device containing a residual amount of an opioid analgesic substance therein;
- (b) an amount of deactivating material including an amount of an activated carbon anti-abuse substance in said container for ~~treating~~ deactivating said residual opioid substance in said patch device on contact,

wherein said container is configured such that
insertion of said skin-worn patch device properly
oriented into said container ~~will causes~~ said abusable
substance in said skin-worn patch device to contact
~~said anti-abuse deactivating substance material;~~ and
(c) closure device for closing said disposable container
thereby capturing said skin-worn patch device.

47 (previously presented). A system as in claim 46
wherein said opioid includes fentanyl.

48 (currently amended). A system as in claim 46 wherein a
portion of ~~said anti-abuse substance deactivating material~~
contains an amount of an agent selected from antagonists,
irritants and mixtures thereof.

49 (currently amended). A skin-worn transdermal patch
device for the administration of an abusable substance to a
patient, comprising:

(a) ~~an anti-abuse a deactivating layer in said patch device~~
~~containing an amount of an deactivating material that~~
~~comprises one or more active anti-abuse substance~~
~~deactivating substances for treating deactivating said~~
~~abusable substance on contact, said one or more anti-~~
~~abuse deactivating substance substances being selected~~
from the group consisting of active binding agents
~~including activated carbon for said abusable substance~~
in said patch device, co-soluble antagonists, irritants

- and combinations thereof disposed in said patch device
deactivating layer;
- (b) a source layer containing said abusable substance in
said patch device;
- (c) an impermeable separator membrane situated between said
anti-abuse layer and said source layer preventing
contact therebetween during normal use of said patch
when said patch device is adhered to the skin of a
user; and
- (d) ~~an extension~~ a membrane removal device connected to
said separator membrane and provided with an aspect
~~that situated to adhesively adheres attach~~ to the skin
of a user when said patch is applied;
wherein said aspect and said patch are configured such
that upon removal of said patch from skin to which said
patch is adhered said aspect remains adhered to skin
and remains adhered to the skin of said user when the
patch is removed in a manner with sufficient adhesion
to withdraw cause said separator membrane to be
withdrawn from between said anti-abuse deactivating
layer substance and said source layer upon removal of
said patch from the skin of said user thereby allowing
the anti-abuse layer to contact the abusable substance
so that the deactivating layer contacts the source
layer.

50 (currently amended). A device as in claim 49 wherein said abusable substance is an opioid and said ~~anti-abuse~~ deactivating substance material is substantially activated carbon.

51 (currently amended). A system as in claim 49 50 wherein a portion of said ~~anti-abuse~~ substance activated carbon contains an amount of an agent selected from the group consisting of antagonists, irritants and mixtures thereof.

52 (new). A system as in claim 49 wherein said deactivating material contains a binding agent that prevents separate extraction of said abusable substance of interest using a solvent selected from the group consisting of water, ethanol or combinations thereof.

53 (new). A system as in claim 49 wherein said deactivating material includes activated carbon.

54 (new). A system as in claim 52 wherein said deactivating material includes activated carbon.

55 (new). A system as in claim 52 wherein said deactivating material includes an amount of an agent selected from the group consisting of antagonists, irritants and combinations thereof.

56 (new). A system as in claim 49 wherein said deactivating material comprises:

- (a) carbon in an activated state in a quantity sufficient to bind said opioid in said patch, and

- (b) carbon that contains an amount of an incorporated species selected from the group consisting of irritating agents, antagonist agents and combinations thereof; and
- (c) wherein said species is released from the carbon of (b) upon an attempt to solvent extract said abusable substance from the carbon of (a).

57(new). A system as in claim 56 wherein said deactivating material includes an amount of an irritant.

58(new). A system as in claim 56 wherein said deactivating material includes an antagonist.

59(new). A system as in claim 46 wherein said deactivating material comprises:

- (a) carbon in an activated state in a quantity sufficient to bind said opioid in said patch, and
- (b) carbon that contains an amount of an incorporated species selected from the group consisting of irritating agents, antagonist agents and combinations thereof; and
- (c) wherein said species is released from the carbon of (b) upon an attempt to solvent extract said opioid from the carbon of (a).

60(new). A disposal system for a skin-worn transdermal patch device containing residual amount of an abusable substance after use thereof on a patient, said system comprising:

- (a) a disposal container separate from and independent of said skin-worn patch device and having an opening therein for receiving said skin-worn patch device;
 - (b) an amount of deactivating material in said container which deactivates said abusable substance on contact further comprising:
 - (1) carbon in an activated state in a quantity sufficient to bind said opioid in said patch;
 - (2) carbon that contains an amount of an incorporated species selected from the group consisting of irritating agents, antagonist agents and combinations thereof; and
 - (3) wherein said species are releasable from the carbon in (2) upon attempt to solvent extract said abusable substance from the carbon of (1).
- and wherein said container is configured such that insertion of said skin-worn patch device properly oriented into said container causes said abusable substance in said skin-worn patch device to contact said deactivating material; and
- (c) closure device for closing said disposal container thereby capturing said skin-worn patch device.

61(new). A system as in claim 60 wherein said container is in the form of a flexible pouch.

62 (new) . A system as in claim 60 wherein said closure device includes an adhesive seal.

63 (new) . A system as in claim 61 wherein said closure device includes an adhesive seal.

64 (new) . A disposal system as in claim 60 wherein said abusable substance is an opioid.

65 (new) . A system as in claim 64 wherein said opioid includes fentanyl.

66 (new) . A disposal system as in claim 60 wherein extraction solvents include water, ethanol and combinations thereof.

67 (new) . A disposal system as in claim 66 wherein said abusable substance is an opioid.

68 (new) . A disposal pouch for the deactivation of a used opioid transdermal patch comprising:

- (a) an amount of deactivating material further comprising:
 - (1) carbon in an activated state in a quantity sufficient to bind said opioid in said patch;
 - (2) carbon that contains an amount of an incorporated species selected from the group consisting of irritating agents, antagonist agents and combinations thereof; and
 - (3) wherein said species are releasable from the carbon in (2) upon attempt to solvent extract said opioid from the carbon of (1) .